Psoriasis With Leg Involvement, a New Difficult-to-Treat Area: A Cohort Study of Patients Treated With Risankizumab

Federico Bardazzi; Federica Filippi; Martina Mussi; Claudia Lasagni; Laura Bigi; Giulia Odorici; Francesca Peccerillo; Miriam Rovesti; Francesca Satolli; Michela Tabanelli; Sandra Schianchi; Vito Di Lernia; Marco Manfredini

doi:10.5826/dpc.1403a171

Psoriasis With Leg Involvement, a New Difficult-to-Treat Area: A Cohort Study of Patients Treated With Risankizumab

Authors

Federico Bardazzi Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, Division of Dermatology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Federica Filippi Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, Division of Dermatology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Martina Mussi Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, Division of Dermatology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Claudia Lasagni Clinica Dermatologica, Dipartimento delle Medicine Specialistiche AOU Policlinico di Modena, Modena, Italy
Laura Bigi Clinica Dermatologica, Dipartimento delle Medicine Specialistiche AOU Policlinico di Modena, Modena, Italy
Giulia Odorici Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
Francesca Peccerillo Dermatology Unit, Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Miriam Rovesti Department of Dermatology, University of Parma, Parma, Italy
Francesca Satolli Department of Dermatology, University of Parma, Parma, Italy
Michela Tabanelli Dermatology Unit, AUSL Romagna, Ravenna, Ravenna, Italy
Sandra Schianchi Department of Dermatology, 'M Bufalini' Hospital, Cesena, Italy
Vito Di Lernia Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda Unità Sanitaria Locale-Istituto di Ricovero e Cura a Carattere Scientifico di Reggio Emilia, Reggio Emilia, Italy
Marco Manfredini Clinica Dermatologica, Dipartimento delle Medicine Specialistiche AOU Policlinico di Modena, Modena, Italy

Keywords:

psoriasis, difficult-to-treat, risankizumab, legs, biologic, treatment, PASI

Abstract

Introduction: Historically, difficult-to-treat areas in psoriasis included face, scalp, folds, genitalia, nails and palmoplantar region. Recent studies have found that lower limbs behave like a “new” difficult-to-treat area, as it can be the only site of residual disease even in patients undergoing biologic therapies.

Objectives: We aimed to evaluate whether legs had different response rates and response times to treatment with a new biologic drug, risankizumab, than other body sites.

Methods: We conducted a real-life, observational, retrospective, multicentric study, including patients affected by moderate-to-severe psoriasis with legs involvement and undergoing biological therapy with risankizumab for more than 16 weeks. The Psoriasis Area Severity Index (PASI) and Leg-PASI were collected at T0 and at week 16, 28, 40, 52, 64 and 76. Statistical analysis using T student test and linear regression analysis were performed.

Results: A total of 124 patients were included. The difference between the improvement percentage respect to baseline was statistically significant at week 16 and 28, demonstrating that Leg-PASI improved less than PASI. From the linear regression it was deduced that the slope is statistically less steep for Leg-PASI than for overall PASI, confirming that this site responds more slowly to the therapy.

Conclusions: Leg response to risankizumab appears to differ significantly from other body-sites in the first weeks of treatment, even if after 28 weeks statistical significance is lost. Our preliminary finding suggests that risankizumab can be considered an effective treatment for legs psoriasis, but with longer response times than other areas demonstrating the relative nature of resistance to treatment of this district.

References

Boehncke WH. Systemic Inflammation and Cardiovascular Comorbidity in Psoriasis Patients: Causes and Consequences. Front Immunol. 5 aprile 2018;9:579.

Kragballe K. Management of difficult to treat locations of psoriasis. Scalp, face, flexures, palm/soles and nails. Curr Probl Dermatol. 2009;38:160–71.

Kivelevitch D, Frieder J, Watson I, Paek SY, Menter MA. Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas. Expert Opin Pharmacother. aprile 2018;19(6):561–75.

Bardazzi F, Viviani F, Filippi F, Carpanese MA, Piraccini BM, Abbenante D. The legs: An underestimated difficult-to-treat area of psoriasis. Dermatol Ther. giugno 2022;35(6):e15485.

Hjuler KF, Iversen L, Rasmussen MK, Kofoed K, Skov L, Zachariae C. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. agosto 2019;181(2):332–7.

Katsuo K, Honda T, Kabashima K. Improvement of recalcitrant psoriatic lesions on the lower legs by changing the injection site of secukinumab from the abdomen to lower legs. J Dermatol. febbraio 2020;47(2):e54–5.

Murari A, Singh KN. Lund and Browder chart—modified versus original: a comparative study. Acute Crit Care. novembre 2019;34(4):276–81.

Montes de Oca Pedrosa A, Oakley A, Rogers J, Rangaitaha Epiha M. PASI vs PO-PASI: Patient-Oriented PASI (PO-PASI) is comparable to clinician score PASI. Australas J Dermatol. febbraio 2022;63(1):e67–70.

Thaçi D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. settembre 2015;73(3):400–9.

Mastorino L, Susca S, Megna M, Siliquini N, Quaglino P, Ortoncelli M, et al. Risankizumab shows high efficacy and maintenance in improvement of response until week 52. Dermatol Ther. maggio 2022;35(5):e15378.

Won SH, Shin BS, Bae KN, Son JH, Shin K, Kim HS, et al. Which Areas Are Still Left in Biologics Responsive Korean Patients with Moderate to Severe Plaque Psoriasis. Ann Dermatol. febbraio 2023;35(1):6–10.